BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 32727849)

  • 1. Intermittent enzyme replacement therapy with recombinant human β-galactosidase prevents neuraminidase 1 deficiency.
    Luu AR; Wong C; Agrawal V; Wise N; Handyside B; Lo MJ; Pacheco G; Felix JB; Giaramita A; d'Azzo A; Vincelette J; Bullens S; Bunting S; Christianson TM; Hague CM; LeBowitz JH; Yogalingam G
    J Biol Chem; 2020 Sep; 295(39):13556-13569. PubMed ID: 32727849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracerebroventricular enzyme replacement therapy with β-galactosidase reverses brain pathologies due to GM1 gangliosidosis in mice.
    Chen JC; Luu AR; Wise N; Angelis R; Agrawal V; Mangini L; Vincelette J; Handyside B; Sterling H; Lo MJ; Wong H; Galicia N; Pacheco G; Van Vleet J; Giaramita A; Fong S; Roy SM; Hague C; Lawrence R; Bullens S; Christianson TM; d'Azzo A; Crawford BE; Bunting S; LeBowitz JH; Yogalingam G
    J Biol Chem; 2020 Sep; 295(39):13532-13555. PubMed ID: 31481471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical and molecular characterization of novel mutations in GLB1 and NEU1 in patient cells with lysosomal storage disorders.
    Kwak JE; Son MY; Son YS; Son MJ; Cho YS
    Biochem Biophys Res Commun; 2015 Feb; 457(4):554-60. PubMed ID: 25600812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enzyme replacement for GM1-gangliosidosis: Uptake, lysosomal activation, and cellular disease correction using a novel β-galactosidase:RTB lectin fusion.
    Condori J; Acosta W; Ayala J; Katta V; Flory A; Martin R; Radin J; Cramer CL; Radin DN
    Mol Genet Metab; 2016 Feb; 117(2):199-209. PubMed ID: 26766614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lysosomal multienzyme complex: pros and cons of working together.
    Bonten EJ; Annunziata I; d'Azzo A
    Cell Mol Life Sci; 2014 Jun; 71(11):2017-32. PubMed ID: 24337808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Orientation of three lysosomal enzymes in the mouse inner ear and hearing loss in enzyme gene deficiency].
    Guo YK; Xie DH; Yang XM
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Feb; 31(1):79-84. PubMed ID: 16562682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of beta-galactosidase and elastin binding protein in lysosomal and nonlysosomal complexes of patients with GM1-gangliosidosis.
    Caciotti A; Donati MA; Boneh A; d'Azzo A; Federico A; Parini R; Antuzzi D; Bardelli T; Nosi D; Kimonis V; Zammarchi E; Morrone A
    Hum Mutat; 2005 Mar; 25(3):285-92. PubMed ID: 15714521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of beta-galactosidase mutations on the expression of the canine lysosomal multienzyme complex.
    Kreutzer R; Kreutzer M; Sewell AC; Techangamsuwan S; Leeb T; Baumgärtner W
    Biochim Biophys Acta; 2009 Oct; 1792(10):982-7. PubMed ID: 19607915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of the beta-galactosidase-carboxypeptidase complex in GM1-gangliosidosis and beta-galactosialidosis fibroblasts.
    D'Agrosa RM; Hubbes M; Zhang S; Shankaran R; Callahan JW
    Biochem J; 1992 Aug; 285 ( Pt 3)(Pt 3):833-8. PubMed ID: 1497621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular mechanisms of pathogenesis in a glycosphingolipid and a glycoprotein storage disease.
    d'Azzo A; Bonten E
    Biochem Soc Trans; 2010 Dec; 38(6):1453-7. PubMed ID: 21118106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term, high dose enzyme replacement therapy in sialidosis mice.
    Wang D; Bonten EJ; Yogalingam G; Mann L; d'Azzo A
    Mol Genet Metab; 2005 Jul; 85(3):181-9. PubMed ID: 15979029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elimination of abnormal sialylglycoproteins in fibroblasts with sialidosis and galactosialidosis by normal gene transfer and enzyme replacement.
    Oheda Y; Kotani M; Murata M; Sakuraba H; Kadota Y; Tatano Y; Kuwahara J; Itoh K
    Glycobiology; 2006 Apr; 16(4):271-80. PubMed ID: 16361247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzymatic activity of lysosomal carboxypeptidase (cathepsin) A is required for proper elastic fiber formation and inactivation of endothelin-1.
    Seyrantepe V; Hinek A; Peng J; Fedjaev M; Ernest S; Kadota Y; Canuel M; Itoh K; Morales CR; Lavoie J; Tremblay J; Pshezhetsky AV
    Circulation; 2008 Apr; 117(15):1973-81. PubMed ID: 18391110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elastogenesis in cultured dermal fibroblasts from patients with lysosomal beta-galactosidase, protective protein/cathepsin A and neuraminidase-1 deficiencies.
    Tatano Y; Takeuchi N; Kuwahara J; Sakuraba H; Takahashi T; Takada G; Itoh K
    J Med Invest; 2006 Feb; 53(1-2):103-12. PubMed ID: 16538002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterodimerization of the sialidase NEU1 with the chaperone protective protein/cathepsin A prevents its premature oligomerization.
    Bonten EJ; Campos Y; Zaitsev V; Nourse A; Waddell B; Lewis W; Taylor G; d'Azzo A
    J Biol Chem; 2009 Oct; 284(41):28430-28441. PubMed ID: 19666471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transient high-level expression of beta-galactosidase after transfection of fibroblasts from GM1 gangliosidosis patients with plasmid DNA.
    Balestrin RC; Baldo G; Vieira MB; Sano R; Coelho JC; Giugliani R; Matte U
    Braz J Med Biol Res; 2008 Apr; 41(4):283-8. PubMed ID: 18392450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Galactosialidosis: preclinical enzyme replacement therapy in a mouse model of the disease, a proof of concept.
    Cadaoas J; Hu H; Boyle G; Gomero E; Mosca R; Jayashankar K; Machado M; Cullen S; Guzman B; van de Vlekkert D; Annunziata I; Vellard M; Kakkis E; Koppaka V; d'Azzo A
    Mol Ther Methods Clin Dev; 2021 Mar; 20():191-203. PubMed ID: 33426146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impaired elastic-fiber assembly by fibroblasts from patients with either Morquio B disease or infantile GM1-gangliosidosis is linked to deficiency in the 67-kD spliced variant of beta-galactosidase.
    Hinek A; Zhang S; Smith AC; Callahan JW
    Am J Hum Genet; 2000 Jul; 67(1):23-36. PubMed ID: 10841810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical Enzyme Replacement Therapy with a Recombinant β-Galactosidase-Lectin Fusion for CNS Delivery and Treatment of GM1-Gangliosidosis.
    Weesner JA; Annunziata I; Yang T; Acosta W; Gomero E; Hu H; van de Vlekkert D; Ayala J; Qiu X; Fremuth LE; Radin DN; Cramer CL; d'Azzo A
    Cells; 2022 Aug; 11(16):. PubMed ID: 36010656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sialidase NEU3 action on GM1 ganglioside is neuroprotective in GM1 gangliosidosis.
    Allende ML; Lee YT; Byrnes C; Li C; Tuymetova G; Bakir JY; Nicoli ER; James VK; Brodbelt JS; Tifft CJ; Proia RL
    J Lipid Res; 2023 Dec; 64(12):100463. PubMed ID: 37871851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.